Fisher Biosciences strengthens its reagent portfolio through acquisition of BioImage


Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies. BioImage complements Fisher Biosciences' existing Cellomics business. BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution(R) technology. Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.

"The addition of BioImage further enhances our portfolio of high content cell-based assays and reagents," said Ron Lowy, president and chief executive officer of Fisher Biosciences. "Adding BioImage's Redistribution IP, assays, cell-lines and services to our already strong offering of high content screening instrumentation, software, siRNA and assay reagent kits, provides a more complete range of options to customers and strengthens Fisher's leadership position in high content screening."

Other news from the department business & finance

Most read news

More news from our other portals